View in EDS

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.

Saved in:
Bibliographic Details
Title: MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.
Authors: Fürstenau M; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Robrecht S; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Schneider C; Division of Chronic Lymphocytic Leukemia, Department of Internal Medicine III, University of Ulm, Ulm, Germany., Tausch E; Division of Chronic Lymphocytic Leukemia, Department of Internal Medicine III, University of Ulm, Ulm, Germany., Giza A; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Ritgen M; Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany., Bittenbring J; Department of Internal Medicine I (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg, Germany., Hebart H; Department of Hematology and Oncology, Stauferklinikum, Mutlangen, Germany., Schöttker B; Hämatologisch-Onkologische Schwerpunktpraxis Würzburg, Würzburg, Germany., Illert AL; Department of Medicine III, School of Medicine, Technical University of Munich, Munich, Germany., Graeven U; Department of Hematology and Oncology, Kliniken Maria Hilf GmbH, Mönchengladbach, Germany., Stoltefuß A; Department of Hematology and Oncology, Evangelisches Krankenhaus Hamm, Hamm, Germany., Heinrich B; Hämatologisch-Onkologische Praxis Heinrich/Bangerter, Augsburg, Germany., Eckert R; Department of Hematology, Oncology, Stem Cell Transplantation, and Palliative Care, Klinikum Stuttgart, Katharinenhospital, Stuttgart, Germany., Fink A; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Stumpf J; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Fischer K; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Al-Sawaf O; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Simon F; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Kleinert F; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Weiss J; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Kreuzer KA; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Schilhabel A; Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany., Brüggemann M; Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany., Langerbeins P; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Stilgenbauer S; Division of Chronic Lymphocytic Leukemia, Department of Internal Medicine III, University of Ulm, Ulm, Germany., Eichhorst B; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Hallek M; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Cramer P; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany.
Source: Blood [Blood] 2025 Mar 20; Vol. 145 (12), pp. 1282-1292.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39883943
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Fürstenau+M%22">Fürstenau M</searchLink>; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Robrecht+S%22">Robrecht S</searchLink>; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Schneider+C%22">Schneider C</searchLink>; Division of Chronic Lymphocytic Leukemia, Department of Internal Medicine III, University of Ulm, Ulm, Germany.<br /><searchLink fieldCode="AU" term="%22Tausch+E%22">Tausch E</searchLink>; Division of Chronic Lymphocytic Leukemia, Department of Internal Medicine III, University of Ulm, Ulm, Germany.<br /><searchLink fieldCode="AU" term="%22Giza+A%22">Giza A</searchLink>; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Ritgen+M%22">Ritgen M</searchLink>; Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany.<br /><searchLink fieldCode="AU" term="%22Bittenbring+J%22">Bittenbring J</searchLink>; Department of Internal Medicine I (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg, Germany.<br /><searchLink fieldCode="AU" term="%22Hebart+H%22">Hebart H</searchLink>; Department of Hematology and Oncology, Stauferklinikum, Mutlangen, Germany.<br /><searchLink fieldCode="AU" term="%22Schöttker+B%22">Schöttker B</searchLink>; Hämatologisch-Onkologische Schwerpunktpraxis Würzburg, Würzburg, Germany.<br /><searchLink fieldCode="AU" term="%22Illert+AL%22">Illert AL</searchLink>; Department of Medicine III, School of Medicine, Technical University of Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Graeven+U%22">Graeven U</searchLink>; Department of Hematology and Oncology, Kliniken Maria Hilf GmbH, Mönchengladbach, Germany.<br /><searchLink fieldCode="AU" term="%22Stoltefuß+A%22">Stoltefuß A</searchLink>; Department of Hematology and Oncology, Evangelisches Krankenhaus Hamm, Hamm, Germany.<br /><searchLink fieldCode="AU" term="%22Heinrich+B%22">Heinrich B</searchLink>; Hämatologisch-Onkologische Praxis Heinrich/Bangerter, Augsburg, Germany.<br /><searchLink fieldCode="AU" term="%22Eckert+R%22">Eckert R</searchLink>; Department of Hematology, Oncology, Stem Cell Transplantation, and Palliative Care, Klinikum Stuttgart, Katharinenhospital, Stuttgart, Germany.<br /><searchLink fieldCode="AU" term="%22Fink+A%22">Fink A</searchLink>; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Stumpf+J%22">Stumpf J</searchLink>; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Fischer+K%22">Fischer K</searchLink>; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Al-Sawaf+O%22">Al-Sawaf O</searchLink>; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Simon+F%22">Simon F</searchLink>; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Kleinert+F%22">Kleinert F</searchLink>; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Weiss+J%22">Weiss J</searchLink>; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Kreuzer+KA%22">Kreuzer KA</searchLink>; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Schilhabel+A%22">Schilhabel A</searchLink>; Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany.<br /><searchLink fieldCode="AU" term="%22Brüggemann+M%22">Brüggemann M</searchLink>; Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany.<br /><searchLink fieldCode="AU" term="%22Langerbeins+P%22">Langerbeins P</searchLink>; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Stilgenbauer+S%22">Stilgenbauer S</searchLink>; Division of Chronic Lymphocytic Leukemia, Department of Internal Medicine III, University of Ulm, Ulm, Germany.<br /><searchLink fieldCode="AU" term="%22Eichhorst+B%22">Eichhorst B</searchLink>; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Hallek+M%22">Hallek M</searchLink>; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Cramer+P%22">Cramer P</searchLink>; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227603509%22">Blood</searchLink> [Blood] 2025 Mar 20; Vol. 145 (12), pp. 1282-1292.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7603509 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1528-0020 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200064971%22">00064971 </searchLink><i>NLM ISO Abbreviation: </i>Blood <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39883943
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/blood.2024026685
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1282
    Titles:
      – TitleFull: MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Fürstenau M
      – PersonEntity:
          Name:
            NameFull: Robrecht S
      – PersonEntity:
          Name:
            NameFull: Schneider C
      – PersonEntity:
          Name:
            NameFull: Tausch E
      – PersonEntity:
          Name:
            NameFull: Giza A
      – PersonEntity:
          Name:
            NameFull: Ritgen M
      – PersonEntity:
          Name:
            NameFull: Bittenbring J
      – PersonEntity:
          Name:
            NameFull: Hebart H
      – PersonEntity:
          Name:
            NameFull: Schöttker B
      – PersonEntity:
          Name:
            NameFull: Illert AL
      – PersonEntity:
          Name:
            NameFull: Graeven U
      – PersonEntity:
          Name:
            NameFull: Stoltefuß A
      – PersonEntity:
          Name:
            NameFull: Heinrich B
      – PersonEntity:
          Name:
            NameFull: Eckert R
      – PersonEntity:
          Name:
            NameFull: Fink A
      – PersonEntity:
          Name:
            NameFull: Stumpf J
      – PersonEntity:
          Name:
            NameFull: Fischer K
      – PersonEntity:
          Name:
            NameFull: Al-Sawaf O
      – PersonEntity:
          Name:
            NameFull: Simon F
      – PersonEntity:
          Name:
            NameFull: Kleinert F
      – PersonEntity:
          Name:
            NameFull: Weiss J
      – PersonEntity:
          Name:
            NameFull: Kreuzer KA
      – PersonEntity:
          Name:
            NameFull: Schilhabel A
      – PersonEntity:
          Name:
            NameFull: Brüggemann M
      – PersonEntity:
          Name:
            NameFull: Langerbeins P
      – PersonEntity:
          Name:
            NameFull: Stilgenbauer S
      – PersonEntity:
          Name:
            NameFull: Eichhorst B
      – PersonEntity:
          Name:
            NameFull: Hallek M
      – PersonEntity:
          Name:
            NameFull: Cramer P
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 20
              M: 03
              Text: 2025 Mar 20
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1528-0020
          Numbering:
            – Type: volume
              Value: 145
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Blood
              Type: main
ResultId 1